Ascendis Pharma A/S (ASND) Earnings Date, Estimates & Call Transcripts → How Biden has already won 2024 (From Porter & Company) (Ad) Free ASND Stock Alerts $122.80 -1.24 (-1.00%) (As of 05/16/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateSep. 3EstimatedActual EPS (Feb. 7) -$1.66 Beat By $0.49 Consensus EPS (Feb. 7) -$2.15 Get Ascendis Pharma A/S Earnings AlertsEnter your email address below to receive the latest news and earnings results for ASND and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueASND Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ASND Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… Ascendis Pharma A/S Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($2.16)($2.16)($2.16)Q2 20242($1.76)($1.07)($1.42)Q3 20242($1.40)($0.50)($0.95)Q4 20242($0.95)($0.17)($0.56)FY 20247($6.27)($3.90)($5.09)ASND Earnings Date and InformationAscendis Pharma A/S last posted its quarterly earnings data on February 7th, 2024. The biotechnology company reported ($1.66) earnings per share for the quarter, beating analysts' consensus estimates of ($2.15) by $0.49. The company had revenue of $148.62 million for the quarter, compared to analysts' expectations of $97.02 million. Ascendis Pharma A/S has generated ($9.61) earnings per share over the last year (($9.61) diluted earnings per share). Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.69) to ($0.26) per share. Ascendis Pharma A/S has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, September 3rd, 2024 based off prior year's report dates.Read More Ascendis Pharma A/S Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 9/3/2024Estimated)------- 2/7/2024Q4 2023($2.15)($1.66)+$0.49($1.66)$97.02 million$148.62 million11/7/2023Q3 2023($2.63)($3.12)($0.49)($3.12)$52.54 million$52.02 million9/5/2023Q2 2023($2.68)($2.35)+$0.33($2.35)$41.73 million$51.59 million4/27/2023Q1 2023($2.84)($2.12)+$0.72($2.12)$24.53 million$36.04 million2/16/2023Q4 2022($2.50)($3.78)($1.28)($3.78)$20.31 million$23.38 million11/2/2022Q3 2022($2.52)($3.05)($0.53)($3.05)$10.67 million$15.41 million Get the Latest News and Ratings for ASND and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. 8/10/2022Q2 2022($2.11)($1.54)+$0.57($1.54)$7.07 million$6.51 million5/11/2022Q1 2022($2.25)($2.48)($0.23)($2.48)$5.89 million$7.66 million 3/2/2022Q4 2021($2.57)($2.14)+$0.43($2.14)$2.78 million$5.60 million 11/9/2021Q3 2021($2.60)($1.47)+$1.13($1.73)$1.60 million$1.31 million 8/24/2021Q2 2021($2.75)($2.50)+$0.25($3.01)$1.46 million$1.23 million 5/26/2021Q1 2021($2.06)($1.17)+$0.89($1.41)$1.94 million$0.90 million Ascendis Pharma A/S Earnings - Frequently Asked Questions When is Ascendis Pharma A/S's earnings date? Ascendis Pharma A/S has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, September 3rd, 2024 based off last year's report dates. Learn more on ASND's earnings history. Did Ascendis Pharma A/S beat their earnings estimates last quarter? In the previous quarter, Ascendis Pharma A/S (NASDAQ:ASND) reported ($1.66) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.15) by $0.49. Learn more on analysts' earnings estimate vs. ASND's actual earnings. How much revenue does Ascendis Pharma A/S generate each year? Ascendis Pharma A/S (NASDAQ:ASND) has a recorded annual revenue of $288.08 million. How much profit does Ascendis Pharma A/S generate each year? Ascendis Pharma A/S (NASDAQ:ASND) has a recorded net income of -$521.07 million. ASND has generated -$9.61 earnings per share over the last four quarters. What is Ascendis Pharma A/S's EPS forecast for next year? Ascendis Pharma A/S's earnings are expected to grow from ($4.69) per share to ($0.26) per share in the next year. More Earnings Resources from MarketBeat Related Companies: CERE Earnings Date LEGN Earnings Date VKTX Earnings Date JAZZ Earnings Date ITCI Earnings Date CYTK Earnings Date ELAN Earnings Date ROIV Earnings Date BPMC Earnings Date IONS Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Home Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong Earnings This page (NASDAQ:ASND) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyThe 1,000X Crypto PlaybookTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.